COVID-19 Press Briefing

March 10, 2021
Daily Change in COVID-19 Cases, US
January 22, 2020 – March 8, 2021

TOTAL Cases Reported Since 1/22/20
28,937,762

NEW Cases Reported to CDC on 3/8/21
41,237

Change in 7-Day Case Average
-14.8%

Current 7-Day Case Average (3/2/21 - 3/8/21)
55,773

Prior 7-Day Case Average (2/23/21 - 3/1/21)
65,461

Reported 7-day moving average* of COVID-19 cases has decreased 78% since January 11, 2021

Peaks in New Cases and Highest 7-Day Moving Average

<table>
<thead>
<tr>
<th></th>
<th>Highest Daily Number of New Cases</th>
<th>Highest 7-Day Moving Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current</td>
<td>314,172 (1/8/21)</td>
<td>249,360 (1/11/21)</td>
</tr>
<tr>
<td>2nd Peak</td>
<td>75,192 (7/17/20)</td>
<td>67,278 (7/23/20)</td>
</tr>
<tr>
<td>1st Peak</td>
<td>42,597 (4/6/20)</td>
<td>31,933 (4/12/20)</td>
</tr>
</tbody>
</table>
New Admissions of Patients with Confirmed COVID-19
August 1, 2020 – March 7, 2021

Patients Currently Hospitalized with COVID on 3/7/21
35,205

New Admissions on 3/7/21
4,155

Peak in New Admissions (1/5/21)
18,007

Change in 7-Day Average of New Admissions
-14.9%

Current 7-Day Average of New Admissions (3/1/21 – 3/7/21)
4,946

Prior 7-Day Average of New Admissions (2/22/21 – 2/28/21)
5,812

Reported 7-day moving average of hospitalizations has decreased 70% since January 9, 2021
Daily Change in COVID-19 Deaths, United States
January 22, 2020 – March 8, 2021

TOTAL Deaths Reported Since 1/22/2020
524,695

NEW Deaths Reported to CDC on 3/8/21
845

Change in 7-Day Death Average
-12.5%

Current 7-Day Death Average (3/2/21 - 3/8/21)
1,646

Prior 7-Day Death Average (2/23/21 - 3/1/21)
1,881

Forecasted Total Deaths by 3/27/21
540,000-564,000
AVOID TRAVEL

STAY 6 FEET APART

WEAR A MASK

AVOID CROWDS

AVOID TRAVEL
SARS-CoV-2 Vaccine Distribution Strategy Aligned to CDC Phases

Total adults - 267 million

**Phase 1a (~24M)**
- Health care personnel
- Long-term care facility residents

**Phase 1b (~49M)**
- Frontline essential workers
- Persons aged 75 years and older

**Phase 1c (~129M)**
- Persons aged 65-74 years
- Persons aged 16-64 years with high-risk conditions
- Essential workers not recommended in Phase 1b

**Phase 2 (~65M)**
- All people aged 16 years or older not in Phase 1, who are recommended for vaccination
Selected Special Populations for SARS-CoV-2 Vaccination

- Pregnant individuals
  - ~3.7 million births in US (2019)\(^1\)

- Adolescents and children
  - ~73 million individuals aged 0-18 years in the US (2019)\(^2\)

- Immunocompromised individuals
  - i.e. individuals with immunosuppressive medical conditions (primary immunodeficiencies, HIV, etc.) or receiving immunosuppressive treatment/chemotherapy
  - Estimated around 3% of US adults (~7-8 million individuals)\(^3\)

\(^1\)CDC, NCHS, 2020
\(^2\)Census.gov
\(^3\)Harpaz, JAMA, 2016
SARS-CoV-2 Vaccination for Special Populations: Selected Questions

- What is the safety and immunogenicity profile of SARS-CoV-2 vaccines in certain special populations?

- What is the duration of the immune response to vaccination in certain special populations?

- What is the efficacy of SARS-CoV-2 vaccination on reducing disease and transmission in certain special populations?
SARS-CoV-2 Vaccination: Pregnant Individuals

- The American College of Obstetricians and Gynecologists (ACOG) recommends that SARS-CoV-2 vaccines should not be withheld from pregnant individuals
  - Pregnant individuals may choose to receive a COVID-19 vaccine
  - A conversation with their clinicians may help them decide

- CDC has established V-safe pregnancy registry to follow outcomes among vaccinated pregnant individuals

- Pfizer/BioNTech launched randomized, placebo-controlled study to evaluate safety/immunogenicity in pregnant individuals
SARS-CoV-2 Vaccination: Adolescents and Children

- **Age ranges for currently authorized SARS-CoV-2 vaccines**
  - Moderna: EUA persons aged 18 years and older
  - Pfizer/BioNTech: EUA persons aged 16 years and older
  - Johnson & Johnson: EUA persons aged 18 years and older

- **Vaccine safety and immunogenicity studies in adolescents and children ongoing and planned**
  - Pfizer/BioNTech study in persons aged 12-15 years: fully enrolled
  - Moderna TeenCOVE study in persons aged 12-17 years: fully enrolled
  - Trials in younger children will follow (i.e. Moderna KidCOVE)
  - J & J studies planned
SARS-CoV-2 Vaccination: Special Populations- Other Considerations

- **People with HIV**
  - People with stable HIV infection included in trials, though data are limited
  - HHS HIV/AIDS Guidelines recommend people with HIV should receive SARS-CoV-2 vaccines (regardless of CD4 or viral load) because the potential benefits outweigh potential risks

- **Highly allergic individuals**
  - Studies planned